Compare with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs SUN PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES SUN PHARMA ALKEM LABORATORIES/
SUN PHARMA
 
P/E (TTM) x 21.4 58.1 36.8% View Chart
P/BV x 4.9 4.3 114.4% View Chart
Dividend Yield % 1.0 0.9 109.7%  

Financials

 ALKEM LABORATORIES   SUN PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-21
SUN PHARMA
Mar-21
ALKEM LABORATORIES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs3,150654 481.9%   
Low Rs2,224339 656.7%   
Sales per share (Unadj.) Rs741.4139.6 531.0%  
Earnings per share (Unadj.) Rs135.39.5 1,420.9%  
Cash flow per share (Unadj.) Rs158.318.2 870.0%  
Dividends per share (Unadj.) Rs30.007.50 400.0%  
Avg Dividend yield %1.11.5 73.9%  
Book value per share (Unadj.) Rs616.8193.6 318.5%  
Shares outstanding (eoy) m119.572,399.34 5.0%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x3.63.6 102.0%   
Avg P/E ratio x19.952.1 38.1%  
P/CF ratio (eoy) x17.027.3 62.2%  
Price / Book Value ratio x4.42.6 170.0%  
Dividend payout %22.278.8 28.2%   
Avg Mkt Cap Rs m321,2441,190,430 27.0%   
No. of employees `000NANA-   
Total wages/salary Rs m16,21068,622 23.6%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m88,650334,981 26.5%  
Other income Rs m2,3328,592 27.1%   
Total revenues Rs m90,982343,573 26.5%   
Gross profit Rs m19,42441,616 46.7%  
Depreciation Rs m2,74620,800 13.2%   
Interest Rs m5891,414 41.7%   
Profit before tax Rs m18,42127,994 65.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2435,147 43.6%   
Profit after tax Rs m16,17822,847 70.8%  
Gross profit margin %21.912.4 176.4%  
Effective tax rate %12.218.4 66.2%   
Net profit margin %18.26.8 267.6%  
BALANCE SHEET DATA
Current assets Rs m69,288304,421 22.8%   
Current liabilities Rs m36,041161,456 22.3%   
Net working cap to sales %37.542.7 87.9%  
Current ratio x1.91.9 102.0%  
Inventory Days Days20149 13.1%  
Debtors Days Days6699 67.0%  
Net fixed assets Rs m34,825336,682 10.3%   
Share capital Rs m2392,399 10.0%   
"Free" reserves Rs m73,517462,229 15.9%   
Net worth Rs m73,756464,628 15.9%   
Long term debt Rs m3438,981 3.8%   
Total assets Rs m104,114641,103 16.2%  
Interest coverage x32.320.8 155.2%   
Debt to equity ratio x00 24.0%  
Sales to assets ratio x0.90.5 163.0%   
Return on assets %16.13.8 425.6%  
Return on equity %21.94.9 446.1%  
Return on capital %25.76.2 413.2%  
Exports to sales %22.10-   
Imports to sales %00-   
Exports (fob) Rs m19,555NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,55584,493 23.1%   
Fx outflow Rs m2,46730,334 8.1%   
Net fx Rs m17,08854,159 31.6%   
CASH FLOW
From Operations Rs m12,64961,704 20.5%  
From Investments Rs m-9,9855,362 -186.2%  
From Financial Activity Rs m-2,718-59,805 4.5%  
Net Cashflow Rs m-175,964 -0.3%  

Share Holding

Indian Promoters % 57.1 54.5 104.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 19.6 34.5 56.7%  
FIIs % 5.4 14.4 37.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 42.9 45.5 94.2%  
Shareholders   81,869 662,384 12.4%  
Pledged promoter(s) holding % 0.0 5.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   CIPLA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    AUROBINDO PHARMA    

Yellow Ad

Advertisement

A One Stock Gift in 1990 Turns into Rs 130 Crores

In 2017, Ravi made headlines by calling a leading business news channel with a surprising announcement - his grandfather had left him 20,000 shares of only one stock.

And on the day of his call - these shares were worth Rs 130 crore.

Can you guess which is this company?

It's MRF.

Ravi's story is one of the amazing stories of becoming Crorepati from a single stock.

But the question is, how to find that one stock with crorepati potential?

To find the answer to this million-dollar question, join our 'One Stock Crorepati' MEGA summit on 30th June, where we will reveal details of what we call a potential 'crorepati' stock...

Learn more



Today's Market

Sensex Zooms 462 Points, Nifty Ends Near 15,700; Auto & FMCG Stocks Rally(Closing)

Indian share markets ended the week on a firm note tracking positive global cues.

Related Views on News

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

Sun Pharma Zooms 10% as June Quarter Earnings Beat Estimates (Views On News)

Jul 30, 2021

Here's a rundown on Sun Pharma's June quarter results.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks(Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Why Tata Power Share Price is Falling(Views On News)

Jun 14, 2022

Here's why shares of Tata Power have fallen in recent days.

Is it Time to Start Buying Stocks Selectively?(Profit Hunter)

Jun 16, 2022

Some sectors have corrected by 50%. Do they merit a look?

Best Monopoly Stocks to Own in 2022(Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

When Will the Stock Market Recover?(Views On News)

Jun 15, 2022

This is how you can tell the market is going to recover.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jun 24, 2022 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS